ISRG vs RTX: Which Is the Better Buy?

Side-by-side comparison of Intuitive Surgical, Inc. and RTX Corporation β€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-09-25.
Intuitive Surgical, Inc. Β· Healthcare
$399.52
+22.4% upside to fair value
Med Conviction Grade B High Quality
VS
RTX Corporation Β· Industrials
$193.54
+33.0% upside to fair value
Med Conviction Grade B High Quality
QuantHub Verdict
RTX has more upside to fair value (+33.0%). These are model outputs β€” not personalized investment advice. See all research β†’
Valuation & Fundamentals
Metric ISRG RTX
Current Price $399.52 $193.54
Fair Value Estimate $488.97 $257.36
Upside to Fair Value +22.4% +33.0%
Market Cap $141.1B $260.9B
Forward P/E β€” β€”
EV / EBITDA 30.7x 18.1x
Price / Sales 12.8x 2.8x
Price / FCF 44.0x 21.7x
Revenue Growth YoY +18.5% +14.5%
Gross Margin 66.7% 20.3%
Operating Margin 31.3% 11.2%
Return on Equity 17.8% 11.8%
Dividend Yield 0% 1.46%
FCF Yield 2.28% 4.6%
Analyst Consensus Strong Buy Buy
Investment Thesis
ISRG β€” Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and commercializes the da Vinci surgical system and the Ion endoluminal system, along with instruments, accessories, training, and digital solutions that drive a large installed-base and recurring-revenue model. Business quality is high: TTM gross margin of 66.7%, operating margin of 31.3%, net margin of 28.4%, ROE of 17.8%, and revenue growth of 18.5% with …
RTX β€” RTX Corporation
RTX Corporation is a $260.85 billion aerospace and defense conglomerate operating three segments β€” Collins Aerospace, Pratt & Whitney, and Raytheon β€” serving commercial aviation, military, and government customers worldwide with 180,000 employees. The business quality is high: it holds intangible-asset and switching-cost advantages rooted in long-cycle engine programs, proprietary defense electro…
Accumulation Zones
Metric ISRG RTX
Zone Low $366.73 $193.02
Zone High $415.62 $218.76
In Buy Zone? Yes Yes
← ISRG Research    RTX Research β†’    All Research